|
AN2728 is a boron-containing drug candidate that as of 2015 was under development by Anacor Pharmaceuticals for the topical treatment of psoriasis and atopic dermatitis (atopic eczema).〔〔Moustafa F, Feldman SR. (A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology ). Dermatol Online J. 2014 May 16;20(5):22608. PMID 24852768〕 It is a phosphodiesterase-4 inhibitor, mainly acting on phosphodiesterase 4B (PDE4B).〔 Chemically, AN2728 is a phenoxybenoxaborole;〔 the boron atom is essential for its binding activity. Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines, proteins believed to be involved in the immune response and inflammation.〔 As of 2015 Anacor was conducting a Phase 3 clinical trial for the treatment of atopic dermatitis,〔Anacor (AN2728 at Anacor website ) Page accessed May 15, 2015〕 and some Phase 2 trials had been completed for the treatment of psoriasis.〔 ==See also== * Anacor * Atopic dermatitis * Psoriasis * Phosphodiesterase * Phosphodiesterase inhibitor * Phases of clinical research 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「AN2728」の詳細全文を読む スポンサード リンク
|